PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 04/23/23

2023-04-23 09:10:30 ET Summary Proof of concept in vivo data from rodent studies and large animal studies for its technology is expected in the 2nd half of 2023. First IND application of PM359 treating patients with chronic granulomatous disease is expected in 2024. Additional...

2023-04-14 13:30:11 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch for a full list of events planned for the week or the Seeking Alpha earnings calendar for com...

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prim...

2023-03-09 09:12:38 ET Prime Medicine press release ( NASDAQ: PRME ): Q4 GAAP EPS of -$0.56 misses by $0.25 . As of December 31, 2022, cash, short-term investments and related party short term investments were $293.9 million, as compared to $269.6 million as of Decembe...

-- Announced preclinical data providing further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function, as well as new preliminary safety analyses demonstrating no detected off-target activity -- -- Nominated PM359, first development candidate for...

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...

Summary Cathie Wood and her ARK Investment Management have just turned their backs on their worst year of performance since the inception of the investing firm. The market continued to systematically dissect any leftover enthusiasm in the growth and technology space, significantly hurti...

Summary This article is the first of a 3-part series discussing 10 sectors that could provide high returns in the future. This first part covers Artificial Intelligence (AI) and Healthcare Technology, highlighting companies and potential growth opportunities. We discuss why you shou...

Summary CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA. During the market turmoil of late last...

-- New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function -- -- New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson&...